Literature DB >> 11072206

Cervical cancer screening programme in Finland.

A Anttila1, P Nieminen.   

Abstract

In Finland, the organised screening programme for the prevention of cervical cancer has been run for over 30 years and has contributed to a 70-80% decrease in the age-adjusted cervical cancer incidence, as well as a reduction in mortality rates. In this article, we describe the operational details of the organised programme - how the target population is defined, how the invitations are done, how smear tests are collected and analysed, how referrals to confirmation and treatment are conducted, and we also provide recent data on the extent and main screening results. The Finnish programme has led to net savings when assessed for its cost-effectiveness. The results encourage the continuation of the screening programme. By introducing modern screening technologies and more systematic quality control activities in the programme, and by expanding the coverage and compliance we expect to further increase the impact of the programme.

Entities:  

Mesh:

Year:  2000        PMID: 11072206     DOI: 10.1016/s0959-8049(00)00311-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  16 in total

1.  Cervical cancer mortality by neighbourhood income in urban Canada from 1971 to 1996.

Authors:  Edward Ng; Russell Wilkins; Michael Fung Kee Fung; Jean-Marie Berthelot
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

Review 2.  Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention.

Authors:  Ana Gradíssimo; Robert D Burk
Journal:  Expert Rev Mol Diagn       Date:  2017-02-20       Impact factor: 5.225

3.  Age-period-cohort analysis of cervical cancer incidence in Hong Kong from 1972 to 2001 using maximum likelihood and Bayesian methods.

Authors:  Gabriel M Leung; Pauline P S Woo; Sarah M McGhee; Annie N Y Cheung; Susan Fan; Oscar Mang; Thuan Q Thach; Hextan Y S Ngan
Journal:  J Epidemiol Community Health       Date:  2006-08       Impact factor: 3.710

4.  Socio-demographic characteristics of participation in the opportunistic German cervical cancer screening programme: results from the EPIC-Heidelberg cohort.

Authors:  David Seidel; Nikolaus Becker; Sabine Rohrmann; Katharina Nimptsch; Jakob Linseisen
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-08       Impact factor: 4.553

5.  Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.

Authors:  Ahti Anttila; Laura Kotaniemi-Talonen; Maarit Leinonen; Matti Hakama; Pekka Laurila; Jussi Tarkkanen; Nea Malila; Pekka Nieminen
Journal:  BMJ       Date:  2010-04-27

6.  Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.

Authors:  Mari Nygård; Anne-Kjersti Daltveit; Steinar O Thoresen; Jan F Nygård
Journal:  BMC Health Serv Res       Date:  2007-01-23       Impact factor: 2.655

7.  Modelling the impact of population-based cytologic screening on cervical cancer incidence and mortality in Hong Kong: an age--period--cohort approach.

Authors:  P P S Woo; T Q Thach; S T B Choy; S M McGhee; G M Leung
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

8.  Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting.

Authors:  L Kotaniemi-Talonen; P Nieminen; A Anttila; M Hakama
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640

9.  Use of private gynaecologist does not relate to better prevention outcomes - an ecological analysis from Finland.

Authors:  Elina Hemminki; Tiina Sevon; Kati Tanninen; Eero Pukkala; Ahti Anttila
Journal:  BMC Health Serv Res       Date:  2006-03-06       Impact factor: 2.655

Review 10.  A comparative analysis of cervical cancer prevention between Nigeria and Nordic countries that have experienced a decline in cervical cancer incidence.

Authors:  Helen I Anyasi; Anna M Foss
Journal:  Int Health       Date:  2021-07-03       Impact factor: 2.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.